Current Approaches to Develop a Live Vaccine against Leishmania major
Novelty in Biomedicine,
Vol. 5 No. 3 (2017),
11 June 2017
Leishmaniasis is an infectious disease that is endemic in 88 countries. Most of the patients after recovery from the infection develop a long-lived natural immunity against re-infection. Reactivation of leishmaniasis subsequent to suppression of the immune system due to HIV infection or administration of systemic immunosuppressive drugs, underscores the importance of developing new drugs and effective vaccine. Despite the many efforts that have been done, there is still no effective vaccine. Up to now, many candidate vaccines from three generations of the vaccine, including Live/killed vaccines, subunit vaccines, and DNA vaccines have been developed and studied. However the sophisticated vaccines, such as prime-boost DNA vaccines are introduced, the best results are obtained from live vaccines. As safety is the most important obstacle to the use of live vaccines, many different approaches have been used to enhance the safety of live vaccine candidates. In this short review, these approaches are summarized.
- live-attenuated vaccine
How to Cite
Akhoundi M, Kuhls K, Cannet A, Votýpka J, Marty P, Delaunay P, et al. A Historical Overview of the Classification, Evolution, and Dispersion of Leishmania Parasites and Sandflies. Bañuls A-L, editor. PLoS Negl Trop Dis. Public Library of Science; 2016;10(3):e0004349.
Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. Public Library of Science; 2012;7(5):e35671.
Hotez P. A handful of “antipoverty” vaccines exist for neglected diseases, but the world’s poorest billion people need more. Health Aff (Millwood). 2011;30(6):1080–7.
Hotez PJ, Alvarado M, Basáñez M-G, Bolliger I, Bourne R, Boussinesq M, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8(7):e2865.
Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305–18.
Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. J Am Acad Dermatol. Elsevier; 2015;73(6):897–908.
Salam N, Al-Shaqha WM, Azzi A. Leishmaniasis in the middle East: incidence and epidemiology. PLoS Negl Trop Dis. Public Library of Science; 2014;8(10):e3208.
Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP NC. Recent advances in leishmaniasis treatment. Int J Infect Dis. 2011;15(8):525–32.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19(1):111–26.
Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther. 2003;8(3):72–5.
Constantinescu CS, Hondowicz BD, Elloso MM, Wysocka M, Trinchieri G, Scott P. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol. 1998;28(7):2227–33.
Lopes MF, Costa-da-Silva AC, DosReis GA, Lopes MF, Costa-da-Silva AC, DosReis GA. Innate immunity to Leishmania infection: within phagocytes. Mediators Inflamm. Hindawi Publishing Corporation; 2014;2014:754965.
Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502–7.
Mendez S, Reckling SK, Piccirillo CA, Sacks D, Belkaid Y. Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J Exp Med. The Rockefeller University Press; 2004 Jul 19;200(2):201–10.
Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016;34(26):2992–5.
Beaumier CM, Gillespie PM, Hotez PJ, Bottazzi ME, Hotez PJ, Hotez PJ, et al. New vaccines for neglected parasitic diseases and dengue. Transl Res. Elsevier; 2013 Sep;162(3):144–55.
Nagill R, Kaur S. Vaccine candidates for leishmaniasis: A review. Int Immunopharmacol. 2011;11(10):1464–88.
Azizi MH, Bahadori M, Dabiri S, Shamsi Meymandi S AF. A History of Leishmaniasis in Iran from 19th Century Onward. Arch Iran Med. 2016;19(2):153–62.
Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006 Mar;123(3):423–38.
Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, et al. Leishmanization: Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine. 2005;23(28):3642–8.
Dunning N. Leishmania vaccines: from leishmanization to the era of DNA technology. Biosci Horizons. Oxford University Press; 2009 Feb 17;2(1):73–82.
Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine. 2008;26(14):1709–24.
Sharifi I, Fekri AR, Aflatonian M-R, Khamesipour A, Nadim A, Mousavi M-RA, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. Elsevier; 1998;351(9115):1540–3.
Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol. 1988;140(4):1274–9.
Shahbazi M, Zahedifard F, Saljoughian N, Doroud D, Jamshidi S, Mahdavi N, et al. Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis. Vet Parasitol. 2015;212(3):130–9.
Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol. 2001;167(12):6967–74.
Aebischer T, Morris L, Handman E. Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance. Int Immunol. 1994;6(10):1535–43.
Daneshvar H, Coombs GH, Hagan P, Phillips RS. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J Infect Dis. 2003 May 15;187(10):1662–8.
Al-Harmni KI. An Experimental Trial of Vaccination Hamsters Against Leishmania donovani Using Attenuated Subcultures. J Sci. 2011;22(4):1–8.
McCall L-I. Leishmanization revisited: Immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis. Vaccine.
Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun. American Society for Microbiology (ASM); 2003;71(9):5121–9.
Datta S, Adak R, Chakraborty P, Haldar AK, Bhattacharjee S, Chakraborty A, et al. Radio-attenuated leishmanial parasites as immunoprophylactic agent against experimental murine visceral leishmaniasis. Exp Parasitol. 2012;130(1):39–47.
Amaral VF, Teva A, Oliveira-Neto MP, Silva AJ, Pereira MS, Cupolillo E, et al. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem Inst Oswaldo Cruz. 2002;97(7):1041–8.
Davoudi N, Khamesipour A, Mahboudi F, McMaster WR. A dual drug sensitive L. major induces protection without lesion in C57BL/6 mice. PLoS Negl Trop Dis. 2014;8(5):e2785.
Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun. 2005;73(10):6372–82.
Zahedifard F, Gholami E, Taheri T, Taslimi Y, Doustdari F, Seyed N, et al. Enhanced Protective Efficacy of Nonpathogenic Recombinant Leishmania tarentolae Expressing Cysteine Proteinases Combined with a Sand Fly Salivary Antigen. McMahon-Pratt D, editor. PLoS Negl Trop Dis. Public Library of Science; 2014;8(3):e2751.
- Abstract Viewed: 504 times
- PDF Downloaded: 428 times